197 related articles for article (PubMed ID: 25676710)
1. The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation.
Pereboeva L; Harkins L; Wong S; Lamb LS
Cancer Immunol Immunother; 2015 May; 64(5):551-62. PubMed ID: 25676710
[TBL] [Abstract][Full Text] [Related]
2. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT
PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319
[TBL] [Abstract][Full Text] [Related]
3. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
4. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.
Bryant NL; Suarez-Cuervo C; Gillespie GY; Markert JM; Nabors LB; Meleth S; Lopez RD; Lamb LS
Neuro Oncol; 2009 Aug; 11(4):357-67. PubMed ID: 19211933
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
Xu Y; Xiang Z; Alnaggar M; Kouakanou L; Li J; He J; Yang J; Hu Y; Chen Y; Lin L; Hao J; Li J; Chen J; Li M; Wu Q; Peters C; Zhou Q; Li J; Liang Y; Wang X; Han B; Ma M; Kabelitz D; Xu K; Tu W; Wu Y; Yin Z
Cell Mol Immunol; 2021 Feb; 18(2):427-439. PubMed ID: 32939032
[TBL] [Abstract][Full Text] [Related]
6. Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.
Riccione K; Suryadevara CM; Snyder D; Cui X; Sampson JH; Sanchez-Perez L
J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741761
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L
Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791
[TBL] [Abstract][Full Text] [Related]
8. IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors.
Joalland N; Chauvin C; Oliver L; Vallette FM; Pecqueur C; Jarry U; Scotet E
J Immunother; 2018 Jun; 41(5):224-231. PubMed ID: 29683891
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid enhances Vδ2 T-lymphocyte antitumor response to human glioma cell lines.
Cimini E; Piacentini P; Sacchi A; Gioia C; Leone S; Lauro GM; Martini F; Agrati C
Int J Immunopathol Pharmacol; 2011; 24(1):139-48. PubMed ID: 21496396
[TBL] [Abstract][Full Text] [Related]
10. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
[TBL] [Abstract][Full Text] [Related]
11. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
[TBL] [Abstract][Full Text] [Related]
12. Gammadelta T cells as immune effectors against high-grade gliomas.
Lamb LS
Immunol Res; 2009; 45(1):85-95. PubMed ID: 19711198
[TBL] [Abstract][Full Text] [Related]
13. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
[TBL] [Abstract][Full Text] [Related]
14. Rapid and transient activation of γδ T cells to IFN-γ production, NK cell-like killing, and antigen processing during acute virus infection.
Toka FN; Kenney MA; Golde WT
J Immunol; 2011 Apr; 186(8):4853-61. PubMed ID: 21383249
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
16. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
Bouet-Toussaint F; Cabillic F; Toutirais O; Le Gallo M; Thomas de la Pintière C; Daniel P; Genetet N; Meunier B; Dupont-Bierre E; Boudjema K; Catros V
Cancer Immunol Immunother; 2008 Apr; 57(4):531-9. PubMed ID: 17764010
[TBL] [Abstract][Full Text] [Related]
17. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
18. Role of γδ T cells in α-galactosylceramide-mediated immunity.
Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
[TBL] [Abstract][Full Text] [Related]
19. CMV-independent lysis of glioblastoma by ex vivo expanded/activated Vδ1+ γδ T cells.
Knight A; Arnouk H; Britt W; Gillespie GY; Cloud GA; Harkins L; Su Y; Lowdell MW; Lamb LS
PLoS One; 2013; 8(8):e68729. PubMed ID: 23950874
[TBL] [Abstract][Full Text] [Related]
20. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma.
Schuessler A; Smith C; Beagley L; Boyle GM; Rehan S; Matthews K; Jones L; Crough T; Dasari V; Klein K; Smalley A; Alexander H; Walker DG; Khanna R
Cancer Res; 2014 Jul; 74(13):3466-76. PubMed ID: 24795429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
